title: Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
abstract: Major chemotherapeutic alternatives for AML have been implemented and compared in three multicenter studies, including a total of 877 adult patients of all ages. The results strongly suggest that myelosuppressive postinduction treatment is a prerequisite for the achievement of long-term remissions. In addition, it was possible to establish an important antileukemic effect of monthly maintenance chemotherapy. Initial results from an intensive two-course preremission therapy concept revealed good practicability and acceptable toxicity, as well as promising response and remission durations by this new approach.
authors.forename: T
authors.initials: T
authors.lastname: Büchner
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: D
authors.initials: D
authors.lastname: Urbanitz
authors.forename: H
authors.initials: H
authors.lastname: Kreutzmann
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: F
authors.initials: F
authors.lastname: Wendt
authors.forename: R
authors.initials: R
authors.lastname: Kuse
authors.forename: A
authors.initials: A
authors.lastname: Mohr
authors.forename: W
authors.initials: W
authors.lastname: Gassmann
authors.forename: H
authors.initials: H
authors.lastname: Löffler
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005860:Germany, West; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008942:Mitoxantrone / Q000008:administration & dosage; D011897:Random Allocation; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D008942:Mitoxantrone; D013866:Thioguanine; D003630:Daunorubicin